Clinical Trials Logo

Parkinsonian Disorders clinical trials

View clinical trials related to Parkinsonian Disorders.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 2

NCT ID: NCT03720691 Not yet recruiting - Clinical trials for Vascular Parkinsonism

rTMS Treatment in Vascular Parkinsonism

rTMS
Start date: December 2018
Phase: N/A
Study type: Interventional

Vascular parkinsonism (VP), parkinsonism resulting from ischemic cerebrovascular disease, was suggested in 1929. The main features are wide-based gait, postural instability, and falls, which make patients with VP frustrated. Currently, the treatment is challenging. Transcranial magnetic stiumation is a noninvasive procedure using electromagnetic induction to stimulate brain, and repetitive transcranial magnetic stiumation (rTMS) can selectively change brain activity to enhance desired effects. The aim of this study is to explore the therapeutic effect of rTMS for the VP.

NCT ID: NCT03572114 Not yet recruiting - Clinical trials for Mitochondrial Diseases

Imaging Neuromelanin and Iron in Dystonia/Parkinsonism

Start date: July 1, 2018
Phase:
Study type: Observational

To generate pilot data to investigate the potential to use in vivo iron- and neuromelanin-quantification as imaging tools for the diagnostic evaluation of movement disorders with predominant dystonia / parkinsonism. To this end we are planning to compare the MR imaging neuromelanin and iron-pattern and content in midbrain, striatum and further brain structures in clinically similar entities and respective, sex- and age-matched healthy controls.

NCT ID: NCT00767546 Not yet recruiting - Parkinson Disease Clinical Trials

Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients

Start date: May 2009
Phase: Phase 1
Study type: Interventional

There's high incidence of seborrhic dermatitis among patients suffering from Parkinson's disease. Seborrhic dermatitis is caused by increased exertion of sebaceous glands. Previous studies have shown an increase of sebum excretion rate in parkinsonian pateints. Other studies demonstrated improvement in seborrhic dermatitis after anticholinergic treatment. From these studies we concluded that there might be hyperactivity of the parasympathetic system among PD patients, that cause increased exertion of sebum, therefore local injection of botulinium toxin, which inhibitis acetyl choline realese, might improve the rash of seborrhic dermatitis. 40 patients suffering from Parkinson disease or other parkinsonian disorders will participate in this study. Before treating the patients with botulinium toxin, we will measure the sebum exertion with the sebumeter device and make clinical evaluation of the rash. We will also take a picture of the rash. Then Botulinium toxin (60- 100 units) will be locally injected to the rash area. Two weeks after the injection the patients will be called and evaluated clinicly and by the sebumeter. Then they will be checked again after 3 weeks, after a month and after two, three and four month's.